Market Overview

With Obstacles To Growth In Sight, Argus Downgrades Clorox

Share:
With Obstacles To Growth In Sight, Argus Downgrades Clorox
Related CLX
Kellogg Discontinues Operations In Crisis-Hit Venezuela; 'Absolutely Unconstitutional,' Says Maduro
Jim Cramer Advises His Viewers On Consolidated Edison, L Brands And More
Dividend Sensei's Portfolio Update 43: The 3 Essential Things All Investors Need To Get Rich (Seeking Alpha)

Margin pressures and private-label competition could impede growth at Clorox Co (NYSE: CLX), according to Argus. 

The Analyst

Argus analyst John Staszak downgraded shares of Clorox from Buy to Hold.

The Thesis

Clorox could see weak organic growth despite benefiting from low-cost operations and strong market share, Staszak said in a Thursday note. (See the analyst's track record here.) 

The analyst said he projects few near-term catalysts for Clorox. 

Helped by a 61-cent-per-share benefit from the recently signed Tax Cuts and Jobs Act, Clorox reported above-consensus EPS for its fiscal second quarter Feb. 2, Staszak said. Citing the lower effective tax rate, Clorox raised its 2018 EPS estimate from a range of $5.47-$5.67 to $6.17-$6.37, the analyst said. The revenue growth guidance was maintained at 1-3 percent.

Argus raised its earnings estimates for 2018 from $5.75 to $6.25, and for 2019 from $6.10 to $6.60.

"Clorox pays a dividend with a yield of about 2.6 percent  and is part of the S&P "Dividend Aristocrats" group — companies that have increased their dividends every year for at least 25 years," Staszak said. 

Clorox shares are fairly valued, with its stable, diverse operations and consistent dividend growth adequately reflected in the current stock price, according to Argus. The firm said it could consider returning the stock to its Buy list if organic growth accelerates and input costs moderate more than expected. 

The Price Action

Clorox shares are up about 1.6 percent over the past year.

Related Links:

Oppenheimer: Waterpik, Arm & Hammer Owner Church & Dwight Well-Positioned In Retail

Morgan Stanley Catches Flack For Colgate-Palmolive Upgrade

Latest Ratings for CLX

DateFirmActionFromTo
Jul 2018Bank of AmericaMaintainsNeutralNeutral
May 2018CitigroupMaintainsNeutralNeutral
May 2018Morgan StanleyMaintainsUnderweightUnderweight

View More Analyst Ratings for CLX
View the Latest Analyst Ratings

Posted-In: Argus John StaszakAnalyst Color Downgrades Analyst Ratings Best of Benzinga

 

Related Articles (CLX)

View Comments and Join the Discussion!